On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Authors
Keywords
-
Journal
NEUROCHEMICAL RESEARCH
Volume 39, Issue 10, Pages 2008-2017
Publisher
Springer Nature
Online
2014-03-29
DOI
10.1007/s11064-014-1293-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Parkinson Disease Psychosis: Update
- (2014) J. H. Friedman BEHAVIOURAL NEUROLOGY
- Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis
- (2013) David Hubbard et al. BEHAVIOURAL PHARMACOLOGY
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Nonmotor Manifestations in Parkinson Disease
- (2012) Oscar Bernal-Pacheco et al. NEUROLOGIST
- Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
- (2012) Tiffini Voss et al. PARKINSONISM & RELATED DISORDERS
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
- (2011) Daniel Weintraub ARCHIVES OF NEUROLOGY
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease
- (2011) Krista McFarland et al. BEHAVIOURAL PHARMACOLOGY
- An update expert opinion on management and research strategies in Parkinson's disease psychosis
- (2011) Jennifer G Goldman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Milestones in Parkinson's disease therapeutics
- (2011) Olivier Rascol et al. MOVEMENT DISORDERS
- Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers
- (2011) Sonia Ancoli-Israel et al. SLEEP MEDICINE
- A 12-Year Population-Based Study of Psychosis in Parkinson Disease
- (2010) Elin B. Forsaa et al. ARCHIVES OF NEUROLOGY
- Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
- (2010) Benedicte Ballanger et al. ARCHIVES OF NEUROLOGY
- Current Use of Clozapine in Parkinson Disease and Related Disorders
- (2010) Alissa A. Thomas et al. CLINICAL NEUROPHARMACOLOGY
- Quetiapine in the treatment of psychosis in Parkinson’s disease
- (2010) Paul Shotbolt et al. Therapeutic Advances in Neurological Disorders
- Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)
- (2009) Clive Ballard et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal Microdialysis
- (2008) S. Boulet et al. JOURNAL OF NEUROSCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now